contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


dagens-aktienyheder-1908-mapspeople-windowmaster-og-ascelia-pharma-ab

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

MapsPeople is a Software-as-a-Service (SaaS) company focusing on digital mapping for indoor navigation. The two primary revenue streams are 1) MapsIndoors which is MapsPeople’s own developed mapping solution for indoor navigation 2) Google Maps partnership with Google. MapsIndoors is the key segment with high double-digit growth rates, and the Google Maps segment is expected to be a more steady business going forward.

MapsPeople has a global presence with offices in Denmark, Germany, Singapore and United States, and customers include some of the largest brands in the world. The company has been listed at Nasdaq First North Premier in Denmark since June 2021.

MapsPeople var i går ude med 2023 guidance på både Contracted ARR og ARR, som selskabet nu guider på. Efter 2022 blev afsluttet med en Contracted ARR på DKK 70,1 mio. (71% vækst) forventer MapsPeople i 2023 en Contracted ARR på mellem DKK 105-115 mio. (forventet vækst på 50-64%) og ARR (defineret som 12 gange månedlig faktureret tilbagevendende omsætning) på mellem DKK 77-87 mio. (forventet vækst på 129-159%). Læs mere her: MapsPeople: Announces 2023 guidance for Contracted ARR and ARR

Ser vi snart nogle grønne tal som investorer? Mapspeople har gang i opsamlingen af nye partnerskaber i USA, der skal understøtte virksomhedens ambitioner om at blive endnu større inden for konferencer og events i det store USA. Læs hele artiklen her. Nu har der jo været heftig tilbagegang i aktien de seneste to år, selvom man gentagende hører gode nyheder, som eksempelvis i deres Q3 report hvor de præsenterede ARR growth på 89% i MapsIndoors, derved en total ARR vækst på 61% YoY. Men hvilken tidshorisont, tror i, at man skal sidde i aktien, før der vil være stabiliseret longterm vækst?

Den 7. oktober udgav HC Andersen Capital en investment case på den danske SaaS-virksomhed, MapsPeople, som en del af et betalt digitalIR samarbejde. Highlights fra casen er præsenteret af HC Andersen Capitals Head of Research, (Growth) @KasperLihn, i denne korte video:

Husk at læse hele vores research disclaimer på https://www.inderes.dk/disclaimer. Dansk:  MapsPeople er en Software-as-a-Service (SaaS) virksomhed med fokus på digital kortlægning til indendørs navigation. De to primære indtægtsstrømme er 1) MapsIndoors som er MapsPeoples egenudviklede kortløsning til indendørs navigation 2) Google Maps partnerskab med Google. MapsIndoors er nøglesegmentet med høje tocifrede vækstrater, og Google Maps-segmentet forventes at være en mere stabil forretning fremadrettet. MapsPeople har en global tilstedeværelse med kontorer i Danmark, Tyskland, Singapore og USA, og kunderne omfatter nogle af de største brands i verden. Virksomheden har været noteret på Nasdaq First North Premier i Danmark siden juni 2021. English:  MapsPeople is a Software-as-a-Service (SaaS) company focusing on digital mapping for indoor navigation. The two primary revenue streams are 1) MapsIndoors which is MapsPeople’s own developed mapping solution for indoor navigation 2) Google Maps partnership with Google. MapsIndoors is the key segment with high double-digit growth rates, and the Google Maps segment is expected to be a more steady business going forward. MapsPeople has a global presence with offices in Denmark, Germany, Singapore, and United States, and customers include some of the largest brands in the world. The company has been listed at Nasdaq First North Premier in Denmark since June 2021.

MapsPeople

WindowMaster is a Danish clean tech company that supplies sustainable indoor climate solutions based on intelligent natural and mixed mode ventilation as well as heat and smoke ventilation solutions. The solutions are for commercial use, primarily in the following six segments: 1) Office, 2) Education institutions, 3) Cultural buildings, 4) Shopping centers, 5) Hospitals and 6) Sports facilities.

In 2015, WindowMaster was acquired by the current majority shareholder and CEO, Erik Boyter, in a management buy-in. Today, the company is a global company with sales subsidiaries in Denmark, Germany, Ireland, Norway, United Kingdom, United States, and Switzerland. The company has been listed at Nasdaq First North in Denmark since October 2020.

Husk at læse hele vores research disclaimer på https://www.inderes.dk/disclaimer. Dansk:  WindowMaster er en dansk clean tech virksomhed, der leverer bæredygtige indeklimaløsninger baseret på intelligent naturlig og blandet ventilation samt varme- og røgventilationsløsninger. Løsningerne er til kommerciel brug, primært i følgende seks segmenter: 1) Kontor, 2) Uddannelsesinstitutioner, 3) Kulturbygninger, 4) Shoppingcentre, 5) Hospitaler og 6) Idrætsfaciliteter. I 2015 blev WindowMaster opkøbt af den nuværende majoritetsaktionær og administrerende direktør, Erik Boyter, i et management buy-in. I dag er virksomheden en global virksomhed med salgsdatterselskaber i Danmark, Tyskland, Irland, Norge, Storbritannien, USA og Schweiz. Virksomheden har været noteret på Nasdaq First North i Danmark siden oktober 2020. English:  WindowMaster is a Danish cleantech company that supplies sustainable indoor climate solutions based on intelligent natural and mixed-mode ventilation as well as heat and smoke ventilation solutions. The solutions are for commercial use, primarily in the following six segments: 1) Office, 2) Education institutions, 3) Cultural buildings, 4) Shopping centers, 5) Hospitals and 6) Sports facilities. In 2015, WindowMaster was acquired by the current majority shareholder and CEO, Erik Boyter, in a management buy-in. Today, the company is a global company with sales subsidiaries in Denmark, Germany, Ireland, Norway, United Kingdom, United States, and Switzerland. The company has been listed at Nasdaq First North in Denmark since October 2020.

WindowMaster International

Ascelia Pharma is a Swedish biotech company with a focus on orphan oncology treatments. They develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. Currently, Ascelia pharma has two pipeline products, namely Orviglance and Oncoral. Orviglance is a novel contrast agent for MR-Imaging developed to improve the detecting and visualization of focal liver lesions (Including liver metastases – and primary tumors) in patients with reduced kidney function. Oncoral is a daily tablet with an established potent anti-tumor effect – even in difficult to treat cancers with the potential to offer better patient outcomes with improved safety following a daily tablet treatment compared to intravenous high-dose infusions at the hospital.

Ascelia Pharma is listed on Nasdaq Small Cap Stockholm with ticker ACE.

Husk at læse hele vores research disclaimer på https://www.inderes.dk/disclaimer. Dansk:  Ascelia Pharma er et svensk biotechselskab med fokus på lægemidler til cancer behandlinger. Selskabet udvikler og kommercialiserer lægemidler, der er målrettet mod medicinske behov som endnu ikke bliver opfyldt og har en klar udviklings- og markedsvej. Ascelia Pharma har to pipeline-produkter, nemlig Orviglance og Oncoral. Orviglance (tidligere Mangoral) er selskabets hovedprodukt. Orviglance er i et fase 3-studie og estimeres at blive godkendt i 2023. Orviglance er et nyt kontrastmiddel til MR-scanning, udviklet til at forbedre påvisning og visualisering af leverlæsioner (inklusiv lever metastaser – og primære tumorer) hos patienter med nedsat nyrefunktion. Derudover har selskabet et fase-2 studie produkt i Oncoral som estimeres at have en færdiggørelsesdato i 2024. Oncoral er en tablet som indtages dagligt med en etableret potent anti-tumor-effekt – selv i svært behandlende kræftformer med potentiale for at tilbyde bedre patientresultater. Oncoral øger patientsikkerheden i og med patienten får en mildere dosis dagligt i form af en tablet, fremfor løbende intravenøse højdosis infusioner på hospitalet. English:  Ascelia Pharma is a Swedish biotech company with a focus on orphan oncology treatments.  They develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. Currently, Ascelia pharma has two pipeline products, namely Orviglance and Oncoral. Orviglance (Former working name Mangoral) is their main product which is a phase 3 study with an estimated completion date in June 2022. Orviglance is a novel contrast agent for MR-Imaging developed to improve the detecting and visualization of focal liver lesions (Including liver metastases – and primary tumors) in patients with reduced kidney function. Oncoral is a phase 2 study with an estimated completion date in 2024. Oncoral is a daily tablet with an established potent anti-tumor effect – even in difficult to treat cancers with the potential to offer better patient outcomes with improved safety following a daily tablet treatment compared to intravenous high-dose infusions at the hospital.

Ascelia Pharma

Dagens aktienyheder med MapsPeople, WindowMaster og Ascelia Pharma AB

Dagens aktienyheder 19/08: <a class="ql-mention" spellcheck="false" href="https://www.linkedin.com/company/54143576/admin/page-posts/published/?page=7&amp;share=true#" data-entity-urn="urn:li:fsd_company:102315" data-guid="7" data-object-urn="urn:li:organization:102315" data-original-text="MapsPeople" data-test-ql-mention="true">MapsPeople</a>, <a class="ql-mention" spellcheck="false" href="https://www.linkedin.com/company/54143576/admin/page-posts/published/?page=7&amp;share=true#" data-entity-urn="urn:li:fsd_company:41637" data-guid="8" data-object-urn="urn:li:organization:41637" data-original-text="WindowMaster" data-test-ql-mention="true">WindowMaster</a> og <a class="ql-mention" spellcheck="false" href="https://www.linkedin.com/company/54143576/admin/page-posts/published/?page=7&amp;share=true#" data-entity-urn="urn:li:fsd_company:2606403" data-guid="9" data-object-urn="urn:li:organization:2606403" data-original-text="Ascelia Pharma AB" data-test-ql-mention="true">Ascelia Pharma AB</a>
MapsPeople er her til morgen ude med regnskabet for Q2 2024. I slutningen af kvartalet var ARR p&#xe5; DKK 55,6 mio. svarende til en v&#xe6;kst p&#xe5; 19% YoY og 5% QoQ. Oms&#xe6;tningen i kvartalet steg til DKK 14,4 mio. svarende til en v&#xe6;kst p&#xe5; 35% YoY. EBITDA (f&#xf8;r engangsposter relateret til to ledere, der forlod selskabet i april) blev forbedret til DKK -8,2 mio. i kvartalet (DKK -15,8 mio. i Q2 2023). Selskabet fastholder guidance for 2024 om en ARR i slutningen af &#xe5;ret p&#xe5; DKK 72-80 mio. (39-54% v&#xe6;kst), oms&#xe6;tning i 2024 p&#xe5; DKK 58-63 mio. (43-55% v&#xe6;kst) og EBITDA f&#xf8;r engangsposter i 2024 p&#xe5; mellem DKK -25 mio. til -20 mio. V&#xe6;ksten i 2024 ventes at komme med en ligelig fordeling fra EMEA og Nordamerika. P&#xe5; torsdag kl. 14:30 pr&#xe6;senterer MapsPeoples ledelse regnskabet for Q2 2024. Tilmeld dig eventet og stil dine sp&#xf8;rgsm&#xe5;l her: https://www.inderes.dk/videos/mapspeople-presentation-of-q2-2024
Efter&#xa0;<a class="ql-mention" spellcheck="false" href="https://www.linkedin.com/company/54143576/admin/page-posts/published/?page=7&amp;share=true#" data-entity-urn="urn:li:fsd_company:41637" data-guid="6" data-object-urn="urn:li:organization:41637" data-original-text="WindowMaster" data-test-ql-mention="true">WindowMaster</a> aflagde regnskab for f&#xf8;rste halv&#xe5;r af 2024 i fredags har vi opdateret vores investment case one-pager. Hvis WindowMaster kan replikere de gode resultater fra f&#xf8;rste halv&#xe5;r i andet halv&#xe5;r, vil selskabet overg&#xe5; nuv&#xe6;rende 2024 guidance-intervaller p&#xe5; oms&#xe6;tning og EBITDA. L&#xe6;s mere her, hvor du ogs&#xe5; kan tilg&#xe5; og se ledelsens pr&#xe6;sentation af H1 2024 rapporten fra i fredags: https://www.inderes.dk/research/windowmaster-one-pager-strong-h1-2024-results-with-a-record-high-order-intake
Pharma Equity Group: Interview med CEO Thomas K. Sels&#xf8; om f&#xf8;rste halv&#xe5;r og forventninger til fremtiden &#x2013; lyt til interviewet her: https://www.inderes.dk/videos/pharma-equity-group-interview-med-ceo-thomas-kaas-selso-ifm-aflaeggelse-af-halvarsregnskab-2024
Disclaimer:&#xa0;<a class="ql-mention" spellcheck="false" href="https://www.linkedin.com/company/54143576/admin/page-posts/published/?page=7&amp;share=true#" data-entity-urn="urn:li:fsd_company:54143576" data-guid="5" data-object-urn="urn:li:fsd_company:54143576" data-original-text="HC Andersen Capital" data-test-ql-mention="true">HC Andersen Capital</a> modtager betaling fra selskaberne for en Digital IR aftale.
Jesper Thomsen - 19/08-2024 kl. 09:03

Stay up to date with our newsletter